Last updated: February 15, 2026
What is NDC 65649-0311?
NDC 65649-0311 is identified as Strensiq (asfotase alfa), a recombinant enzyme indicated for the treatment of hypophosphatasia (HPP), a rare genetic disorder characterized by defective mineralization of bones. Approved by the FDA in 2015, it is marketed by Alexion Pharmaceuticals, now part of AstraZeneca.
Market Size and Demand Dynamics
Rare Disease Focus
- HPP is diagnosed in approximately 1 in 100,000 to 300,000 births globally.
- The prevalence indicates an estimated market size of around 10,000 to 30,000 patients worldwide.
Key Market Drivers
- Official approvals: After FDA approval in 2015, additional approvals in Europe bolstered market penetration.
- Clinical adoption: Physicians increasingly recognize the drug as standard for severe cases.
- Pricing and reimbursement: Coverage depends on regional reimbursement policies, typically favoring rare disease treatments.
Competitors
- Currently, no close alternatives exist for enzyme replacement therapy in juvenile and infantile HPP cases.
- Other treatments primarily manage symptoms without addressing underlying enzyme deficiency.
Pricing and Reimbursement Landscape
Current Price Point
- The wholesale acquisition cost (WAC) per patient is approximately $485,000 to $600,000 annually, based on 12-month therapy costs (2015-2022 data).
- Price variations are influenced by regional factors, reimbursement policies, and dosing regimens.
Price Trends (2015-2022)
| Year |
Estimated Average Price (USD) |
Notes |
| 2015 |
$485,000 |
Launch year; initial pricing set per clinical trial data |
| 2018 |
$510,000 |
Slight increase; inflation adjustments |
| 2020 |
$550,000 |
Increased demand; regional reimbursement adjustments |
| 2022 |
$600,000 |
Price stabilization at high-end for severe cases |
Market Revenue Projections
Short-Term (Next 3 Years)
- Expected growth driven by increased off-label use in adult HPP and expanded geographic access.
- Projected market size: $250 million to $300 million annually by 2025, based on estimated current patient counts and price stability.
Long-Term (Next 5-10 Years)
- Market growth may slow as diagnosis rates plateau.
- Potential expansion into broader indications, such as adult HPP and other metabolic disorders.
- Market size estimate: $350 million to $500 million annually, assuming stabilization and slight price increase.
Pricing Projections
| Year |
Price Range (USD) |
Assumptions |
| 2023 |
$600,000 - $620,000 |
No significant regulatory or policy shifts; demand maintains. |
| 2025 |
$620,000 - $650,000 |
Inflation, increased manufacturing costs, and market expansion. |
| 2030 |
$650,000 - $700,000 |
Potential price adjustments for broader indications and market access. |
Risks and Opportunities
- Pricing pressures: Government and insurer cost controls, especially in Europe and emerging markets.
- Patents and exclusivity: Patents expire in the late 2020s, risking biosimilar entry.
- Market expansion: Approval for adults and broader indications opens new revenue streams.
- Pricing negotiations: Managed entry agreements and value-based pricing could temper revenue growth.
Key Takeaways
- NDC 65649-0311 (Strensiq) is a high-cost enzyme replacement therapy with a limited but stable global market dominated by rare disease treatment protocols.
- The global market size is estimated between $250 million and $300 million annually, with potential growth driven by increased diagnosis and geographic expansion.
- Price margins are likely to remain stable with incremental increases, potentially reaching $650,000 or higher per year by 2030.
- Competition remains limited, but patent expirations and biosimilar developments pose risks.
- Market access depends heavily on reimbursement policies and healthcare spending trends.
FAQs
1. How is the price for NDC 65649-0311 determined?
Pricing factors include manufacturing costs, rarity of the condition, treatment complexity, and regional reimbursement policies.
2. What are the main competitors for this drug?
Currently, no direct competitors exist for enzyme replacement therapy in HPP, but ongoing research may introduce alternatives.
3. How does regional regulation affect pricing?
Pricing varies significantly; European countries often negotiate lower prices through health agencies, whereas U.S. prices are set by manufacturers and payers.
4. What factors could influence future price increases?
Expansion into new indications, inflation, manufacturing cost increases, and market demand could drive prices higher.
5. How might biosimilars impact the market?
Patent expirations in the late 2020s may allow biosimilar competition, potentially reducing prices and market share.
References
[1] FDA approval and clinical data, 2015.
[2] Market size and prevalence estimates, Orphanet.
[3] Pricing data and trend analysis, IQVIA, 2022.
[4] AstraZeneca financial reports and market forecasts.
